Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales28@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Pharmaceutical raw materials Powder Prasugrel
Product Overview:
Pratgrel, a thienopyridine antiplatelet drug developed by Eli Lilly and Japanese drugmaker DaiichiSankyo, is a precursor drug that is metabolized by cytochrome P450 in the liver to form an active molecule that binds to the platelet P2Y12 receptor to exert anti-platelet aggregation activity. Clinical studies have proved that the 60 mg dose has a better anticoagulant effect than the 300 mg standard dose of clopidogrel and the 600 mg increased dose, which can reduce the combined risk of heart attack, stroke and death from heart disease by 20%, and the effect is fast and good, with good drug resistance and bioavailability, and the toxicity is also low.
Pharmaceutical raw materials Powder Prasugrel Attributes
CAS:150322-43-3
MF:C20H20FNO3S
MW:373.44
EINECS:801-962-1
Specification: 99% min Prasugrel
Sample:Prasugrel Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Pharmaceutical raw materials Powder Prasugrel Details
Prasugrel Usage and Synthesis.
Pragrel also has a stronger performance than clopidogrel in interventional surgery for stable angina pectoris and acute coronary syndrome, but the stronger the antiplatelet effect is, the more likely it is to cause bleeding. The key question now is how we can identify patients at high risk of thrombosis and how we can identify those at high risk of bleeding in the clinic, so that pragrel and clopidogrel can be used differently in the two high-risk groups, both to reduce coronary thrombosis and avoid major bleeding.
Uses of Prasugrel.
In vitro study of Prasugrel.
Prasugrel, a novel orally active thiophenyl pyridinium, has faster, higher and more reliable platelet aggregation inhibition than clopidogrel, indicating that it is metabolized in vivo as an active metabolite with selective P2Y(12) antagonistic activity.
Product method of Prasugrel.
